메뉴 건너뛰기
Cancer
Volumn 109, Issue 2, 2007, Pages 341-
Generalizability of cancer clinical trial results [1]
Author keywords

[No Author keywords available]
Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
EID: 33846254007     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22390     Document Type: Letter
Times cited : (6)
References (3)
  • 1
    • 33646872630 scopus 로고    scopus 로고
    • Generalizability of cancer clinical trial results. Prognostic differences between participants and nonparticipants
    • Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results. Prognostic differences between participants and nonparticipants. Cancer. 2006;106: 2452-2458.
    • (2006) Cancer , vol.106 , pp. 2452-2458
    • Elting, L.S.1    Cooksley, C.2    Bekele, B.N.3
  • 2
    • 0025306551 scopus 로고
    • Estimation issues in clinical trials and overviews
    • Pocock SJ, Hughes MD. Estimation issues in clinical trials and overviews. Stat Med. 1990;9:657-671.
    • (1990) Stat Med , vol.9 , pp. 657-671
    • Pocock, S.J.1    Hughes, M.D.2
  • 3
    • 33646888233 scopus 로고    scopus 로고
    • Where next for gefitinib in patients with lung cancer?
    • Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol. 2006; 7:499-507.
    • (2006) Lancet Oncol , vol.7 , pp. 499-507
    • Blackhall, F.1    Ranson, M.2    Thatcher, N.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.